Close

News

RVAC Medicines and A*STAR to Build Capabilities for mRNA Production in Singapore

RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company incubated by CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, and the Agency for Science, Technology and Research (A*STAR) announced the signing of a master research collaboration agreement...

CPhI & P-MEC India expo to encourage cost-effective solutions in India’s march towards a Rs 10.5 lakh crore Pharma Market by 2030

Continuing the winning streak of CPhI & P-MEC India, Informa Markets, the leading international B2B events group is once again back with its 15th edition in an evolved hybrid format to be held from 29th November to 1st December...

Merck Invests € 290 Million in U.S. Drug Safety Testing Capacity

Merck, a leading science and technology company, invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA. This will significantly increase the company’s ability to conduct biosafety testing and analytical development services. Biosafety testing...

Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems

The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched to ensure the growing threats and impacts of antimicrobial resistance are addressed globally. The Food and Agriculture Organization of the United Nations (FAO), the UN Environment Programme (UNEP), the World Health Organization...

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,  announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease...

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Regeneron Pharmaceuticals, Inc.  and CytomX Therapeutics, Inc.  announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform. The collaboration is strategically focused on applying CytomX's...

UPS Completes Acquisition of Bomi Group Multi-National Healthcare Logistics Firm

UPS announced that it has closed on the acquisition of Bomi Group, an industry-leading multi-national healthcare logistics provider. Through the acquisition, the company's healthcare unit, UPS Healthcare, will add temperature-controlled facilities in 14 countries, and 3,000 highly-skilled employees to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »